These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 30988147)
1. Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Jiao Y; Moya B; Chen MJ; Zavascki AP; Tsai H; Tao X; Sutaria DS; Louie A; Boyce JD; Deveson Lucas D; Kim TH; Tsuji BT; Bonomo RA; Drusano GL; Bulitta JB Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988147 [TBL] [Abstract][Full Text] [Related]
2. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Paul M; Silbiger I; Grozinsky S; Soares-Weiser K; Leibovici L Cochrane Database Syst Rev; 2006 Jan; (1):CD003344. PubMed ID: 16437452 [TBL] [Abstract][Full Text] [Related]
3. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Paul M; Lador A; Grozinsky-Glasberg S; Leibovici L Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003344. PubMed ID: 24395715 [TBL] [Abstract][Full Text] [Related]
4. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. Falagas ME; Matthaiou DK; Bliziotis IA J Antimicrob Chemother; 2006 Apr; 57(4):639-47. PubMed ID: 16501057 [TBL] [Abstract][Full Text] [Related]
5. Is there evidence on the optimal duration of aminoglycoside therapy in β-lactam/aminoglycoside combination regimens used for the treatment of gram-negative bacterial infections? A systematic review. Wale YM; Roberts JA; Wolie ZT; Sime FB Int J Antimicrob Agents; 2024 Oct; 64(4):107297. PubMed ID: 39111709 [TBL] [Abstract][Full Text] [Related]
6. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791 [TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
8. Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit? Rahme C; Butterfield JM; Nicasio AM; Lodise TP Diagn Microbiol Infect Dis; 2014 Dec; 80(4):239-59. PubMed ID: 25308565 [TBL] [Abstract][Full Text] [Related]
9. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Paul M; Benuri-Silbiger I; Soares-Weiser K; Leibovici L BMJ; 2004 Mar; 328(7441):668. PubMed ID: 14996699 [TBL] [Abstract][Full Text] [Related]
10. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Paul M; Soares-Weiser K; Grozinsky S; Leibovici L Cochrane Database Syst Rev; 2003; (3):CD003038. PubMed ID: 12917941 [TBL] [Abstract][Full Text] [Related]
11. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Paul M; Dickstein Y; Schlesinger A; Grozinsky-Glasberg S; Soares-Weiser K; Leibovici L Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD003038. PubMed ID: 23813455 [TBL] [Abstract][Full Text] [Related]
12. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Hsueh PR; Chen WH; Luh KT Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243 [TBL] [Abstract][Full Text] [Related]
14. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Paul M; Soares-Weiser K; Grozinsky S; Leibovici L Cochrane Database Syst Rev; 2002; (2):CD003038. PubMed ID: 12076467 [TBL] [Abstract][Full Text] [Related]
15. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Leibovici L; Paul M; Poznanski O; Drucker M; Samra Z; Konigsberger H; Pitlik SD Antimicrob Agents Chemother; 1997 May; 41(5):1127-33. PubMed ID: 9145881 [TBL] [Abstract][Full Text] [Related]
16. Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: A meta-analysis of randomized controlled trials. Lu LC; Lai CC; Chang SP; Lan SH; Hung SH; Lin WT Medicine (Baltimore); 2020 May; 99(19):e19960. PubMed ID: 32384444 [TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Bliziotis IA; Michalopoulos A; Kasiakou SK; Samonis G; Christodoulou C; Chrysanthopoulou S; Falagas ME Mayo Clin Proc; 2005 Sep; 80(9):1146-56. PubMed ID: 16178494 [TBL] [Abstract][Full Text] [Related]
19. Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside. DeJace P; Klastersky J Am J Med; 1986 Jun; 80(6B):29-38. PubMed ID: 3524218 [TBL] [Abstract][Full Text] [Related]
20. Is double coverage of gram-negative organisms necessary? Johnson SJ; Ernst EJ; Moores KG Am J Health Syst Pharm; 2011 Jan; 68(2):119-24. PubMed ID: 21200057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]